Sign in

CIK 0001737287

  • Non-accelerated filer
  • Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
823562771
Phone
+1 650-457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Derivatives Options or other derivatives
  2. 4 Grant or award Director acquired 16,377 shares (grant or award)
  3. 4 Grant or award Director acquired 16,377 shares (grant or award)
  4. 4 Derivatives Options or other derivatives
  5. 4 Open-market sale Chief Technical Officer sold 48,828 shares at an average $26.76 ($1,306,774)
  6. 4 Other disposition Director disposed of 598,935 shares (other)
  7. 4 Other acquisition President and CEO acquired 11,753 shares (other)
  8. 4 Open-market sale 10% owner sold 1,918,755 shares at $29.38 ($56,373,022)
  9. 4 Other acquisition President and CEO acquired 11,753 shares (other)
  10. 4 Other disposition Director disposed of 598,937 shares (other)
  11. 4 Grant or award Chief Technical Officer acquired 37,050 shares (grant or award)
  12. 4 Grant or award Chief Financial Officer acquired 49,400 shares (grant or award)
  13. 4 Grant or award Director acquired 115,333 shares (grant or award)
  14. 4 Grant or award President and CEO acquired 173,000 shares (grant or award)
  15. 4/A Open-market buy Director bought 194,445 shares at $18.00 ($3,500,010)
  16. 4 Other acquisition Director acquired 6,535 shares (other)
  17. 4 Open-market buy Director bought 15,000 shares at $18.00 ($270,000)
  18. 4 Open-market buy Director bought 30,000 shares at $18.00 ($540,000)
  19. 4 Conversion Director acquired 18,716 shares (conversion)
  20. 4 Open-market buy President and CEO bought 40,000 shares at $18.00 ($720,000)

Page 13 of 14 · 275 filings